Results 191 to 200 of about 186,812 (342)

Endomyocardial Fibrosis Associated With Hypereosinophilic Syndrome: Diagnostic and Management Insights From a Case Report

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Endomyocardial fibrosis (EMF) is a rare form of restrictive cardiomyopathy associated with eosinophilic disorders, characterized by apical subendocardial fibrosis and thrombus formation. Cardiac magnetic resonance (CMR) provides a comprehensive, noninvasive evaluation, enabling diagnosis, assessment of disease activity, and guidance of therapy.
Ibrahim Antoun   +3 more
wiley   +1 more source

Eosinophils and the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancers: A Retrospective Study. [PDF]

open access: yesBiomedicines
Suzuki R   +19 more
europepmc   +1 more source

Eosinophils express a functional receptor for interferon alpha: inhibitory role of interferon alpha on the release of mediators [PDF]

open access: bronze, 1996
Delphine Aldebert   +7 more
openalex   +1 more source

Verekitug, a Novel Antibody Antagonist to the TSLP Receptor in Adults with Asthma: A 32‐Week Randomized Phase 1b Multiple Ascending‐Dose Trial

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Verekitug, a novel, high‐affinity, fully human monoclonal antibody targeting thymic stromal lymphopoietin receptor (TSLPR), is in development as a potential treatment for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic obstructive pulmonary disease (COPD).
Dave Singh   +9 more
wiley   +1 more source

Eosinophils Regulate Peripheral B Cell Numbers in Both Mice and Humans [PDF]

open access: bronze, 2014
Tina W. Wong   +3 more
openalex   +1 more source

Eosinophilic Esophagitis [PDF]

open access: yesJAMA, 2019
Craig D, Peiris, James A, Tarbox
openaire   +2 more sources

Straight to Phase III: Model‐Informed Approach Speeds Depemokimab Clinical Development in Interleukin‐5‐Driven Diseases

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Straight to Phase III: Model‐informed approach speeds depemokimab clinical development in interleukin‐5‐driven diseases. IL‐5, a key mediator of type 2 inflammation, underlies various diseases, including severe asthma, CRSwNP, EGPA, and HES. Reduction in blood eosinophil count (BEC), a biomarker of IL‐5 activity, is commonly used to evaluate the ...
Chiara Zecchin   +6 more
wiley   +1 more source

High Blood Eosinophil Count at Stable State is Not Associated with Airway Microbiota Distinct Profile in COPD

open access: yesInternational Journal of COPD
Jeanne-Marie Perotin,1,2 Anaëlle Muggeo,3 Quentin Lecomte-Thenot,3 Audrey Brisebarre,1 Sandra Dury,2 Claire Launois,1,2 Julien Ancel,1,2 Valérian Dormoy,1 Thomas Guillard,3 Gaëtan Deslee1,2 1Université de Reims Champagne-Ardenne, INSERM UMR-S 1250 ...
Perotin JM   +9 more
doaj  

Home - About - Disclaimer - Privacy